Moreover, TAK-243 sensitivity correlates with BCRP expression levels in cancer cell lines of different origins, suggesting BCRP expression can serve as a predictive biomarker of TAK-243 response and a potential therapeutic target for synergistic combinations with TAK-243. The gene discussed is ABCG2; the disease is cancer.